Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Up 846.6% in September

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a significant growth in short interest in September. As of September 30th, there was short interest totalling 140,100 shares, a growth of 846.6% from the September 15th total of 14,800 shares. Based on an average daily volume of 142,000 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.7% of the company’s shares are sold short.

Xilio Therapeutics Stock Performance

NASDAQ XLO opened at $0.80 on Friday. Xilio Therapeutics has a twelve month low of $0.49 and a twelve month high of $2.89. The stock has a fifty day simple moving average of $0.82 and a 200 day simple moving average of $0.98.

Xilio Therapeutics (NASDAQ:XLO) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.01). The business had revenue of $2.36 million for the quarter, compared to analysts’ expectations of $30.00 million. Research analysts predict that Xilio Therapeutics will post -1.26 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Xilio Therapeutics stock. Renaissance Technologies LLC grew its position in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) by 18.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 295,000 shares of the company’s stock after acquiring an additional 45,554 shares during the quarter. Renaissance Technologies LLC owned about 0.80% of Xilio Therapeutics worth $280,000 as of its most recent filing with the Securities & Exchange Commission. 54.29% of the stock is currently owned by hedge funds and other institutional investors.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.